{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:05:15Z","timestamp":1777565115555,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Familial hypercholesterolemia (FH) is an under-diagnosed condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We applied standard laboratory criteria across a large longitudinal electronic medical record database to describe cross-sectional population with possible FH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study of Clalit Health Services members. Subjects who met the General Population MED-PED laboratory criteria, excluding: age &amp;lt;10\u2009years, documentation of thyroid, liver, biliary or autoimmune diseases, a history of chronic kidney disease stage 3 or greater, the presence of urine protein &amp;gt;300\u00a0mg\/l, HDL-C&amp;gt;80\u00a0mg\/dl, active malignancy or pregnancy at the time of testing were considered possible FH. Demographic and clinical characteristics are described at time of diagnosis and at a single index date following diagnosis to estimate the burden on the healthcare system. The patient population is also compared to the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study cohort included 12\u00a0494 subjects with out of over 4.5 million members of Clalit Health Services. The estimated prevalence of FH in Israel was found to be 1:285. These patients are notably positive for, and have a family history of, cardiovascular disease and risk factors. For most of them the LDL-C levels are not controlled, and only a quarter of them are medically treated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>By using the modified MED-PED criteria in a large electronic database, patients with possible FH can be identified enabling early intervention and treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcz327","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:08:05Z","timestamp":1577102885000},"page":"411-417","source":"Crossref","is-referenced-by-count":17,"title":["The characteristics of patients with possible familial hypercholesterolemia\u2014screening a large payer\/provider healthcare delivery system"],"prefix":"10.1093","volume":"113","author":[{"given":"A","family":"Elis","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Leventer-Roberts","sequence":"first","affiliation":[{"name":"Clalit Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bachrach","sequence":"first","affiliation":[{"name":"Clalit Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Lieberman","sequence":"first","affiliation":[{"name":"Medical Policy Division, Clalit Health Services, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Durst","sequence":"first","affiliation":[{"name":"The Center for Research Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Knobler","sequence":"first","affiliation":[{"name":"The Institute of Diabetes, Endocrinology, and Metabolism, Kaplan Medical Center, Rehovot, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Balicer","sequence":"first","affiliation":[{"name":"Clalit Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"2020060803544217300_hcz327-B1","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020060803544217300_hcz327-B2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"2020060803544217300_hcz327-B3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccl.2015.01.001","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol Clin"},{"key":"2020060803544217300_hcz327-B4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia\u2013epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2020060803544217300_hcz327-B5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","article-title":"Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia","volume":"75","author":"Ito","year":"2015","journal-title":"Drugs"},{"key":"2020060803544217300_hcz327-B6","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.2174\/1381612824666181009103440","article-title":"Prevalence, identification, and scouting for familial hypercholesterolaemia including registries","volume":"24","author":"Florentin","year":"2019","journal-title":"Curr Pharm Des"},{"key":"2020060803544217300_hcz327-B7","year":"1999"},{"key":"2020060803544217300_hcz327-B8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"2020060803544217300_hcz327-B9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"key":"2020060803544217300_hcz327-B10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","article-title":"Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes","volume":"134","author":"Williams","year":"2016","journal-title":"Circulation"},{"key":"2020060803544217300_hcz327-B11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacl.2019.01.010","article-title":"LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a)in a large cohort of predominantly genetically verified familial hypercholesterolemia","volume":"13","author":"Bogsrud","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2020060803544217300_hcz327-B12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5551\/jat.41483","article-title":"Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan","volume":"25","author":"Teramoto","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2020060803544217300_hcz327-B13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2147\/CLEP.S176853","article-title":"How well can familial hypercholesterolemia be identified in an electronic health record database?","volume":"10","author":"Mues","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2020060803544217300_hcz327-B14","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jacl.2016.08.001","article-title":"Rapid identification of familial hypercholesterolemia from electronic health records: the SEARCH study","volume":"10","author":"Safarova","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2020060803544217300_hcz327-B15","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.3390\/jpm8040035","article-title":"Patient and provider perspectives on a decision aid for familial hypercholesterolemia","volume":"8","author":"Farwati","year":"2018","journal-title":"J Pers Med"},{"key":"2020060803544217300_hcz327-B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2017.07.004","article-title":"Detection of familial hypercholesterolemia in patients from a general practice database","volume":"29","author":"Casula","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"2020060803544217300_hcz327-B17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12963-014-0032-y","article-title":"Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel","volume":"12","author":"Karpati","year":"2014","journal-title":"Popul Health Metr"},{"key":"2020060803544217300_hcz327-B18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"252","author":"Piepoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"2020060803544217300_hcz327-B19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1258\/acb.2012.012002","article-title":"Opportunistic screening for familial hypercholesterolaemia via a community laboratory","volume":"49","author":"Bell","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"2020060803544217300_hcz327-B20","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"2020060803544217300_hcz327-B21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"2020060803544217300_hcz327-B22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"2020060803544217300_hcz327-B23","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2020060803544217300_hcz327-B24","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"2020060803544217300_hcz327-B25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2020060803544217300_hcz327-B26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s004390050243","article-title":"Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations","volume":"98","author":"Steyn","year":"1996","journal-title":"Hum Genet"},{"key":"2020060803544217300_hcz327-B27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0021-9150(98)00267-6","article-title":"Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations","volume":"143","author":"Couture","year":"1999","journal-title":"Atherosclerosis"},{"key":"2020060803544217300_hcz327-B28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jacl.2015.07.005","article-title":"Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit","volume":"9","author":"Pang","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2020060803544217300_hcz327-B29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5114\/aoms.2016.59700","article-title":"Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland","volume":"12","author":"Pajak","year":"2016","journal-title":"Arch Med Sci"},{"key":"2020060803544217300_hcz327-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacl.2018.09.008","article-title":"Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia","volume":"13","author":"Paquette","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2020060803544217300_hcz327-B31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"2020060803544217300_hcz327-B32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"key":"2020060803544217300_hcz327-B33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.atherosclerosis.2018.06.010","article-title":"Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia","volume":"277","author":"Hagger","year":"2018","journal-title":"Atherosclerosis"},{"key":"2020060803544217300_hcz327-B34","first-page":"731","article-title":"Identifying undiagnosed or undertreated patients with familial hypercholesterolemia from the laboratory records of a tertiary medical center","volume":"45","author":"Haymana","year":"2017","journal-title":"Turk Kardiyol Dern Ars"},{"key":"2020060803544217300_hcz327-B35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40272-014-0116-y","article-title":"Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence","volume":"17","author":"Braamskamp","year":"2015","journal-title":"Paediatr Drugs"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcz327\/32093788\/hcz327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/6\/411\/33356381\/hcz327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/6\/411\/33356381\/hcz327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T07:55:00Z","timestamp":1591602900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/113\/6\/411\/5688752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,12,27]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcz327","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2019,12,27]]}}}